- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07831213
Post-Market Clinical Follow-up (PMCF) Study of Safety and Performance of 300-01 RefillHA Lips
A Post-Market Observational Study of the Safety and Efficacy of RefillHA Lips for Remodelling and Correction of Mild Defects of the Lips.
A Post-Market Observational Study of the Safety and Efficacy of RefillHA Lips for Remodelling and Correction of Mild Defects of the Lips
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This post-market, prospective, non-interventional, open label study is designed to demonstrate the performance and safety of RefillHA Lips in routine clinical practice for remodelling and correction of mild defects of the lips.
Subjects over 18 years old, willing to undergo non-surgical aesthetic procedures with RefillHA Lips will be offered to participate in the study. The investigators will enroll in any subject who receives at least one injection with RefillHA Lips and have provided informed consent. They will follow their routine practice regarding injection technique, volume, and subject follow-up. Treatments will be performed for a single indication or for multiple indications where correction is requested, subject to the advice of the practitioner and in accordance with the product intended use and conditions. Any indication can be retreated at any time throughout the duration of the study, as per routine practice. The area to be treated and injection characteristics - volume, depth, and technique - are all left to the discretion of the practitioner.
The study protocol includes an initial visit (baseline) and follow-up visits at months 1, 3, 6, 9, and 12 from baseline, in accordance with the non-interventional study design. Additional visits are allowed at any time throughout the follow-up period at the patient's request or when deemed necessary. At each visit, in addition to the safety assessment, performance will be evaluated through an area-specific assessment of the lips.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Luoghi di studio
-
-
Israel
-
Lod, Israel, Israele, 7152026
- Reclutamento
- Glyance Ltd
-
Contatto:
- Rachel Shemesh
- Numero di telefono: +972535514894
- Email: rachel@axecium.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Subjects over the age of 18 who are seeking remodelling and/or correction of mild defects of the lips.
Descrizione
Inclusion Criteria:
- Men or women of any race, 18 years of age or older.
- Able to read, understand and sign informed consent.
Exclusion Criteria:
- Subjects with known contraindications to the treatment with RefillHA Lips, as per the device IFU.
- Patients with multiple and/or severe allergies or history of anaphylaxis.
- Pregnant or lactating women (contraindications as per IFU).
- Having received prior dermal filler injections in the six months preceding the study.
- Previously treated with semi-permanent or permanent filler in the intended injection area.
- Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.
- Known hypersensitivity to lidocaine and/or lidocaine HCl or hyaluronic acid.
- Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.
- Undergoing or planning to undergo peeling treatment or laser-/ultrasound-based treatment within 3 weeks before or after injection.
- Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.
- Subject who has a condition or is in a situation that, in the investigator's opinion, may put the subject at significant risk, or may significantly interfere with the subject's participation in the study or with protocol evaluation parameters.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Subjects over 18 years old, willing to undergo non-surgical aesthetic procedures with RefillHA Lips
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Primary endpoint
Lasso di tempo: Up to 56 weeks after treatment
|
The proportion of subjects with Global Aesthetic Improvement Scale (GAIS) scores 1-3 (responders) in the lips at months 6, 9 and 12 after initial injection, as assessed by the investigator (iGAIS). [Scores 1-3 correspond to 'Very much improved', 'Much improved', and 'Improved' (see Section 12.1).] |
Up to 56 weeks after treatment
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- PMCF-300-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .